Costs and Survival Benefits of Cancer Drugs Approved Through the FDA’s Accelerated Pathway

What does faster approval mean for patients, evidence standards, and health care costs?

Your gift is doubled through December 31.

Donate Now
Date
March 23, 2026

The FDA’s accelerated approval pathway allows cancer drugs to reach patients sooner, often based on early trial results rather than proven survival benefit.

Dr. Huseyin Naci discusses findings from a recent BMJ Medicine study examining survival gains and Medicare spending associated with these approvals. Join us to explore what faster approval means for patients, evidence standards, and health care costs.

Speakers

Huseyin Naci, MHS, PhD
London School of Economics and Political Science